This is the board for Aida Pharmaceuticals, a company based in Hangzhou, China. Aida's primary revenue-producing product is an antibiotic named Etimicin but Aida is currently developing other drugs as well. Earnings (late 2007) may be somewhat depressed as there is a new mandate in China which requires hospitals to purchase drugs only from pharmaceutical manufacturers and this has hurt results somewhat as distributors returned sales to Aida. Aida expects that this issue is resolved. Aida's earnings, similar to other Chinese pharmaceutical companies, appear to be highly seasonal with most of the revenues occuring during the fourth quarter.
Revenues/Earnings are as follows (some data is derived from other filings) ($):
|Qtr: ||Rev: ||COGS: ||Gr Pft ||SG&A ||Other ||NI: ||CompNI ||Shs: ||per sh. |
|3Q05 ||$6,249,343 ||$1,543,179 ||$4,706,164 ||$3,210,978 || _ ||$730,540 ||$817,007 ||23,375,000 ||$0.035 |
|4Q05 ||8,445,457 ||4,163,018 ||4,282,439 ||4,903,129 || _ ||-30,452 ||-20,372 ||23,481,849 ||-0.001 |
|1Q06 ||5,331,827 ||2,983,114 ||2,348,713 ||2,327,879 || _ ||14,536 ||58,237 ||25,000,000 ||0.002 |
|2Q06 ||7,284,888 ||3,579,700 ||3,705,188 ||2,803,043 || _ ||398,888 ||414,243 ||25,000,000 ||0.017 |
|3Q06 ||7,023,891 ||3,103,516 ||3,920,375 ||2,481,226 || _ ||919,285 ||968,626 ||25,000,000 ||0.039 |
|4Q06 ||10,002,497 ||4,414,710 ||5,587,787 ||3,688,802 || _ ||120,875 ||296,941 ||27,000,000 ||0.011 |
|1Q07 ||5,296,176 ||2,972,516 ||2,323,660 ||2,164,150 || _ ||-160,204 ||42,574 ||27,000,000 ||0.002 |
|2Q07 ||6,419,476 ||3,605,286 ||2,814,190 ||1,965,568 || _ ||-16,315 ||367,603 ||27,000,000 ||0.014 |
|3Q07 ||7,373,770 ||3,557,685 ||3,816,085 ||2,379,034 || _ ||519,061 ||541,213 ||27,000,000 ||0.020 |
|4Q07 ||10,114,364 ||4,375,195 ||5,739,169 ||2,454,876 || _ ||2,397,283 ||2,193,730 ||27,000,000 ||0.081 |
|1Q08 ||7,652,017 ||3,700,057 ||3,951,960 ||2,984,642 || _ ||-18,980 ||56,193 ||27,000,000 ||0.002 |
|2Q08 ||10,899,924 ||4,731,941 ||6,167,983 ||4,211,180 ||-8,077,264* ||-6,771,364 ||-6,960,862 ||27,000,000 ||-0.26 |
|3Q08 ||11,885,458 ||4,958,239 ||6,927,219 ||4,069,538 || _ ||2,289,681 ||2,361,682 ||27,000,000 ||0.08 |
* During the second quarter of 2008, a company called Nanwang Information Industry Group Co. defaulted on its loans. Aida was the guarantor of Nanwang's loan and had to repay around 50M RMB (about $7,000,000) to make good on Nanwang's default. This resulted in the extraordinary loss per share during the second quarter of 2008. In addition, $1,032,141 was paid out as a consulting fee for previous business development work.
Aida has also won several patent infringement suits against other Chinese companies which were counterfeiting Aida's products. This, combined with the Chinese government's mandate to only purchase pharmaceuticals directly from the manufacturers, could positively impact Aida's bottom line.
While the Etimicin sales seem promising, Aida Pharmaceuticals is really interesting because of the situation regarding their anti-cancer drug under development called Rh-Apo2L. This is being produced by subsidiary of Aida's called Shanghai Qiaer Bio-technology Co., Ltd which is 77.5% owned by Aida. The drug works by triggering apoptosis (programmed cell death) in cancer cells. Phase II testing has shown strong efficacy with fewer side effects than other anti-cancer drugs.
Despite the potential, the share price is possibly depressed since Rh-Apo2L is also being developed separately by Genentech and Amgen in the United States. The basis for Rh-Apo2L appears to be a public research paper published in the U.S.. In China, Qiaer (Aida) began work on the drug while in the U.S., Genentech and Amgen began work on the drug. Genentech and Amgen are obviously much bigger than Aida. Patent situations in China are fledgling and uncertain but this could certainly be an issue. Aida currently has patents on the drug in China while Genetech and Amgen undoubtedly have patents in the U.S.. If Genentech and Amgen feel they have claims over Aida's intellectual property, the dispute could hurt Aida.
The R&D landscape in China is that China can finish clinical trials much faster than the United States due to delays in the U.S. due to FDA approvals. This makes it seem probable that Aida will begin marketing the drug before Genentech and Amgen. Other issues are the lack of or reduced patent protection and enforcement. Chinese companies often manufacture U.S. drugs despite patent protection in the U.S.. Pfizer recently won a landmark suit in China against a Chinese company which was producing Viagra.
However, unlike the Pfizer case, theft of intellectual property doesn't seem to be the issue with Aida. Aida went through all the development of Rh-Apo2L themselves. While the Pfizer case was against a company which copied even the name "Viagra," Aida hasn't taken any intellectual property as far as is known. The coincidence of the name of the drug being co-developed, Rh-Apo2L (recombinant Apo2L), refers to the type of protein and not any trademarked name.
If all goes well with commercialization, the current share price is undoubtedly cheap. If commercialization doesn't go well, the company still has its profitable Etimicin sales as well as other drugs in the pipeline and this may limit the downside risk. Given the current profitable business and the large potential, Aida seems like a very attractive play.
Company's website: http://en.aidapharma.com
Press Releases (abbreviated from full press releases):
3/27/08 Aida Acquires High-Level Research Institute in China (Jiangsu Institute of Microbiology Co.) "The acquisition is expected to yield multiple new products for Aida, including several that are already in clinical trials by China's State Food and Drug Administration."
4/9/2008: Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development "...its recently-acquired research institute in the Jiangsu Province, the Jiangsu Institute of Microbiology Co., Ltd or "JSIM", is developing a new wide-spectrum antibiotic, Wetimicin, in the People's Republic of China. Wetimicin is from the newest generation of amino-glycoside family of antibiotics and is being tested for the treatment of various inflammations, such as respiratory infection, urinogenital infection, soft skin tissue infection as well as infections from trauma and operations, etc. JSIM's scientists believe that it might be safer and more reliable for children and elderly patients than current drug offerings in the marketplace."
4/18/08 Aida Announces New Anti-Cancer Drug Under Development "...it is developing a potential cancer drug that seeks to trigger cell death in certain types of cancer. Vasostatin-Apo2L, a pre-clinical product being developed by Aida's Shanghai Qiaer subsidiary, is a recombinant fusion protein that integrates the function of extracted fragments of Vasostatin, an inhibitor of angiogenesis and tumor growth, with the function of Rh-Apo2L, which induces the apoptosis of cancer cells."
4/22/08 Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website http://en.aidapharma.com
4/24/08: Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition "...it has completed the acquisition of a controlling interest in Jiangsu Institute of Microbiology Co., Ltd. ("JSIM"), one of the leading microbiology research institutes in the People's Republic of China."
4/28/08 Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing "...the Company is compiling data for its Phase 2 testing results of Rh-Apo2L and expects to announce the findings within the next month. The Company previously announced that the target cancers for the drug have been determined and initial results are extremely positive."
12/03/08 Aida Pharmaceutials files 15-12G, certification of notices of termination of registration, with the SEC. This will mean that Aida's shares will move to the pink sheets.
Moderating policy: All positive and negative opinions alike will be allowed and even occasional digressions (within reason) will be allowed. 'Moderating' will be kept to a minimum. The philosophy behind this is that some conflict and differing opinions is normal, that readers can form their own opinions from what they read and that readers usually don't need to be protected from posts by a moderator. Adverse opinions or misinformation can be refuted by other posters. If you feel this policy is inadequate or if you feel you are vulnerable to what others may say, it may be advisable for you to avoid this board. In addition, this board is no substitute for due diligence.